Posted by Michael Wonder on 18 Oct 2022
Noema Pharma receives FDA fast track designation for basimglurant (NOE-101) in trigeminal neuralgia
18 October 2022 - Noema Pharma today announces that the US FDA has granted fast track designation to its mGluR5 inhibitor basimglurant (NOE-101) for the treatment of trigeminal neuralgia.
The FDA authorised Noema Pharma's investigational new drug application to initiate a Phase 2/3 clinical trial of basimglurant in trigemial neuralgia in February 2022.
